The medical community is rapidly adopting long-acting therapeutics maternal pediatric solutions to overcome chronic adherence barriers. However, pregnant women, breastfeeding mothers, and children often face significant delays in accessing these innovative treatments. A recent white paper from the University of Liverpool Centre of Excellence for Long-acting Therapeutics (CELT) addresses these historical disparities. This document synthesizes findings from a July 2025 global workshop focused on bridging research and access gaps.

Overcoming Gaps in Long-Acting Therapeutics Maternal Pediatric Access

Currently, clinical research designs frequently exclude special populations, leading to a scarcity of safety and efficacy data. Consequently, the white paper advocates for inclusive and context-sensitive research protocols. Furthermore, clinicians and researchers must push for harmonized regulatory frameworks that recognize the unique physiological needs of infants and pregnant individuals. Establishing these standards will accelerate the deployment of long-acting formulations in diverse clinical settings.

Strengthening Partnerships for Sustainable Innovation

Sustainable funding remains a critical bottleneck for pediatric drug development. Therefore, the report emphasizes the need for interdisciplinary collaboration among academia, the pharmaceutical industry, and public health organizations. Additionally, culturally responsive implementation strategies are vital to ensure that new therapies reach the most vulnerable populations. Such partnerships will be central to realizing the full potential of long-acting technologies globally.

Frequently Asked Questions

How do long-acting therapeutics benefit pediatric patients?

Long-acting therapeutics reduce the daily pill burden, which significantly improves treatment adherence and quality of life for children with chronic conditions.

Why is regulatory harmonization necessary for maternal health?

Harmonization aligns safety standards across different countries. This alignment allows faster access to life-saving medications for pregnant women who are often excluded from early clinical trials.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Archary M et al. A White Paper on Advancing Long-Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation. Clin Pharmacol Ther. 2026 Apr 14. doi: 10.1002/cpt.70288. PMID: 41981739.

O'Connor McFerran and Quinney Page. Bridging the Gap: Inclusion of Pregnant Women in Clinical Drug Trials. Clin Chem. 2025; 71(1): 1-5.